register

News & Trends - Biotechnology

CSL optimistic of R&D pipeline advancements

Health Industry Hub | November 9, 2022 |

Biotech News: At its annual R&D investor briefing, biotechnology leader CSL demonstrated how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health through its three businesses; CSL Behring, CSL Seqirus and CSL Vifor.

CSL revealed progress and plans in advancing assets that have the potential to disrupt current standards of care in its areas of focus in immunology, haematology, respiratory, cardiovascular and metabolic, transplant, nephrology and vaccines, using its strategic scientific platforms such as plasma protein technology, recombinant technology, cell and gene therapy, and sa-mRNA, adjuvanted, cell-based and egg-based vaccines.

Internal efforts and the Vifor acquisition have seen the R&D pipeline grow around 70% with the majority being late-stage programs. CSL management is optimistic of the future, “conservatively” estimating at least 10 compounds (~20% of the total pipeline) having the potential to be standard of care for the targeted patient groups.

There is potential for approval and launch of the first-ever haemophilia B gene therapy EtranaDez, Phase 3 data for garadacimab – a first-in-class monoclonal antibody in hereditary angioedema, and Phase 3 recruitment completion of CSL112 for reducing the risk of major adverse CV events (MACE) in patients following a heart attack

“CSL is on the leading-edge of innovation in areas we know well and we have strategically and methodically built a pipeline that has never been more robust with diverse sources of innovation, from in-house and external sources, that include the disruptive scientific platforms of gene therapy and sa-mRNA,” said Dr Bill Mezzanotte, Executive Vice President, Head of R&D, and Chief Medical Officer for CSL.

“Our enhanced capabilities across all of our scientific platforms and therapeutic focus areas will help us in our relentless pursuit to deliver on our promise to help patients lead full lives, protect public health and sustainably grow our business in the decades ahead, while providing promising futures for our employees,” he added.    

In fiscal year 2021-2022, CSL invested approximately $1.16 billion in R&D. This includes growing CSL R&D’s footprint locally and internationally in helping to create an integrated global organisation that can conveniently collaborate with institutions everywhere – offering scientists a wide array of opportunities for professional development and enhancing access to external innovation.

In relation to the recent biotechnology incubator collaboration, Dr Andrew Nash, CSL’s Chief Scientific Officer and Senior Vice President of Research, said “Incubator residents will be working in an innovation-driven environment alongside a large and focused CSL R&D team, enabling opportunities for peer-collaboration, learning and sharing of ideas. The strong collaboration between CSL, the University of Melbourne, WEHI, Breakthrough Victoria and now Cicada Innovations has been critical to bring the incubator to fruition and reflects CSL’s values and desire to deliver on our promise to patients worldwide.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.